Spots Global Cancer Trial Database for recommended phase 2 dose
Every month we try and update this database with for recommended phase 2 dose cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Losartan + Sunitinib in Treatment of Osteosarcoma | NCT03900793 | Osteosarcoma | Losartan Sunitinib | 10 Years - 40 Years | University of Colorado, Denver | |
| A Phase I Study, Evaluating the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | NCT05159700 | Advanced Solid ... Advanced Solid ... | PRJ1-3024 | 18 Years - | Zhuhai Yufan Biotechnologies Co., Ltd | |
| A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors | NCT04957290 | Metastatic Cast... | NOX66 NOX66 NOX66 NOX66 NOX66 EBRT | 18 Years - | Noxopharm Limited | |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | NCT02573259 | Part 1 MELANOMA SCCHN OVCA SARCOMA OTHER SOLID TUM... Part 1 and 2 NSCLC UROTHELIAL CARC... | PF-06801591 PF-06801591 | 18 Years - | Pfizer | |
| Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma | NCT01988493 | Carcinoma, Hepa... | Tepotinib 300 m... Tepotinib 500 m... Tepotinib 1000 ... Tepotinib Sorafenib | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | NCT05315167 | Advanced Solid ... Advanced Solid ... | PRJ1-3024 | 18 Years - | Zhuhai Yufan Biotechnologies Co., Ltd | |
| A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | NCT05315167 | Advanced Solid ... Advanced Solid ... | PRJ1-3024 | 18 Years - | Zhuhai Yufan Biotechnologies Co., Ltd | |
| Losartan + Sunitinib in Treatment of Osteosarcoma | NCT03900793 | Osteosarcoma | Losartan Sunitinib | 10 Years - 40 Years | University of Colorado, Denver | |
| A Study of NOX66 and External Beam Radiotherapy in Patients With Metastatic Castration-resistant Prostate Cancer and Other Solid Tumors | NCT04957290 | Metastatic Cast... | NOX66 NOX66 NOX66 NOX66 NOX66 EBRT | 18 Years - | Noxopharm Limited | |
| Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma | NCT04044378 | Effect of Drugs Progression Pediatric Cance... | Famitinib Ifosfamide Camrelizumab | 12 Years - | Peking University People's Hospital | |
| A Dose Escalation Study Of PF-06801591 In Melanoma, Head And Neck Cancer (SCCHN), Ovarian, Sarcoma, Non-Small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors | NCT02573259 | Part 1 MELANOMA SCCHN OVCA SARCOMA OTHER SOLID TUM... Part 1 and 2 NSCLC UROTHELIAL CARC... | PF-06801591 PF-06801591 | 18 Years - | Pfizer | |
| A Study of DBPR112 in Patients With Head and Neck Cancer and EGFR Mutated Lung Cancer | NCT03246854 | Head and Neck C... NSCLC | DBPR112 | 18 Years - 70 Years | National Health Research Institutes, Taiwan | |
| Efficacy, Safety, and Pharmacokinetic of MSC2156119J in Asian Participants With Hepatocellular Carcinoma | NCT01988493 | Carcinoma, Hepa... | Tepotinib 300 m... Tepotinib 500 m... Tepotinib 1000 ... Tepotinib Sorafenib | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| A Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Efficacy of PRJ1-3024 in Subjects With Advanced Solid Tumors | NCT05315167 | Advanced Solid ... Advanced Solid ... | PRJ1-3024 | 18 Years - | Zhuhai Yufan Biotechnologies Co., Ltd |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
